Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.
2.

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.

Russell-Jones D.

Int J Clin Pract. 2010 Sep;64(10):1402-14. doi: 10.1111/j.1742-1241.2010.02465.x. Review.

PMID:
20716148
3.

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.

Werner U, Haschke G, Herling AW, Kramer W.

Regul Pept. 2010 Sep 24;164(2-3):58-64. doi: 10.1016/j.regpep.2010.05.008. Epub 2010 Jun 2. Review.

PMID:
20570597
4.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS.

Endocr Pract. 2009 Sep-Oct;15(6):540-59. Erratum in: Endocr Pract. 2009 Nov-Dec;15(7):768-70.

PMID:
19858063
5.

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

Madsbad S.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. doi: 10.1016/j.beem.2009.03.008. Review.

PMID:
19748064
6.

International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations.

Ceriello A, Colagiuri S.

Diabet Med. 2008 Oct;25(10):1151-6. doi: 10.1111/j.1464-5491.2008.02565.x.

7.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association.; European Association for Study of Diabetes..

Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.

8.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group..

Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

PMID:
18819705
9.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
10.

GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.

Buteau J.

Diabetes Metab. 2008 Feb;34 Suppl 2:S73-7. doi: 10.1016/S1262-3636(08)73398-6. Review.

PMID:
18640589
11.

Standards of medical care in diabetes--2008.

American Diabetes Association..

Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012. No abstract available.

PMID:
18165335
12.

Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes.

Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, Lau J.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004095. Review.

PMID:
15846698
13.

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004096. Review.

PMID:
15674929
14.

Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes.

Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, Avignon A, Boniface H.

Diabetes Care. 2002 Apr;25(4):737-41.

PMID:
11919134

Supplemental Content

Support Center